Interleukin-1 alpha (IL-1α), encoded by the IL1A gene, is initially synthesized as a 31 kDa precursor protein (pro-IL-1α). Unlike many cytokines, the precursor is fully biologically active. It features a conserved ß-trefoil pyramidal barrel structure composed of twelve ß -strands. It contains a distinct nuclear localization sequence (NLS) in its N-terminal region. Intracellularly, the calcium-dependent protease calpain cleaves the precursor into an 18 kDa mature C-terminal form and a 16 kDa N-terminal propiece.
IL-1α is a dual-function cytokine constitutively expressed in epithelial, endothelial, and stromal barrier cells.
- Intracellularly: In its precursor form, it translocates to the cell nucleus where it binds chromatin and acts as a transcription factor regulating cell proliferation and senescence.
- Extracellularly: Upon necrotic tissue injury or cell death, it is released to act as an alarmin (or DAMP). Both the pro- and mature forms bind the IL-1R1 receptor to recruit the IL-1RAcP coreceptor. This triggers the MYD88 and IRAK pathway, driving downstream NF-ß B and MAPK signaling. This process induces the expression of chemokines, recruits neutrophils, and initiates sterile inflammation.
Dysregulation of IL-1α drives numerous inflammatory and malignant disorders. In oncology, tumor-derived IL-1α drives cachexia (muscle and lean mass wasting), tumor angiogenesis, and metastasis. Consequently, targeted therapeutic monoclonal antibodies, such as bermekimab (MABp1), are utilized or investigated in clinical settings to treat advanced cancer cachexia and inhibit tumor progression.
Because IL-1α is heavily concentrated in the epidermis, its overexpression is implicated in severe dermatological conditions. Therapies blocking IL-1 signaling, including the receptor antagonist anakinra and the trap protein rilonacept, are clinically applied to alleviate neutrophilic dermatoses, autoinflammatory syndromes, and systemic inflammatory diseases.




Reviews
There are no reviews yet.